In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

NEW YORK – A first-in-human Phase I trial is underway testing Atavistik Bio's ATV-1601 in patients with AKT1 E17K-mutated solid tumors, the Cambridge, Massachusetts-based company announced this week.

If a progression-free survival readout later this year is positive, the firm will pursue approval in HLA-A2-negative metastatic uveal melanoma.

The regulator is allowing the firm to submit data on 4D-150 from a single Phase III trial and draw on readouts from previously conducted studies in wet AMD.

Under Project Impact, one of four programs backed by $200 million in funds, researchers aim to harmonize EHR data and build an AI model to improve cancer care.